Claim Missing Document
Check
Articles

Found 2 Documents
Search

Acupressure PC6 Self-Care for Hyperemesis Gravidarum during the Covid-19 Pandemic Viventius, Yoshua; Mihardja, Hasan; Djaali, Wahyuningsih
Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education Research Institute Vol. 6 No. - (2022): Proceedings Book of International Conference and Exhibition on The Indonesian M
Publisher : Writing Center IMERI FMUI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69951/proceedingsbookoficeonimeri.v6i-.133

Abstract

Introduction: Most pregnant women (50–90%) generally experience nausea and vomiting during pregnancy, which usually subsides at 16–20 weeks of gestation. Approximately 0.5–2 percent experience severe nausea and vomiting, known as HG, which necessitates hospitalization. Since 2.000, the Ministry of Health of the Republic of Indonesia has been developing acupressure self-care, among other things, by implementing acupressure training (Teknologi Tepat Guna – TTG) for mild complaints about health workers. Objective: This review discusses several studies that demonstrated the effect of acupressure on HG, as well as the mechanism of acupressure, the points used, and treatment strategies. Method: The Google Scholar and PubMed databases were searched for studies published between 2010 and 2020 on how acupressure affects HG using the keywords acupressure, hyperemesis gravidarum, and PC6 point. Randomized clinical trials on human subjects and studies that measured nausea vomiting index in pregnant woman as outcomes were included. Studies that did not include clinical effects of acupressure were excluded. Results: The following studies on HG (n=4) were discovered. These studies suggested that acupressure might be considered to reduce symptoms of nausea and vomiting in pregnant women. Conclusion: Acupressure at PC6 may reduce nausea and vomiting in pregnant women by influencing gastrointestinal function via nerve stimulation to inhibit cerebral cortex function. Self-care acupressure at the PC6 point may be a therapeutic option to reduce HG during the Covid-19 pandemic.
Platelet-Rich Plasma as a Pharmacopuncture Agent in Cervical Myofascial Pain Nareswari, Irma; Kamal, Achmad Fauzi; Mihardja, Hasan; Yunus, Reyhan Eddy; Jusuf, Ahmad Aulia; Harahap, Alida Roswita; Wahyuni, Luh Karunia; Werdhani, Retno Asti; Handayani, Selfi; Rukmindar, Dion
Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education Research Institute Vol. 9 No. - (2025): Proceedings Book of International Conference and Exhibition on The Indonesian M
Publisher : Writing Center IMERI FMUI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69951/proceedingsbookoficeonimeri.v9i-.310

Abstract

Chronic cervical myofascial pain (CMP) is a prevalent musculoskeletal disorder characterized by persistent neck pain, inflammation, functional impairment, and altered pain processing. Conventional treatments, including pharmacological therapy and physical rehabilitation, often provide limited and temporary relief. Increasing evidence suggests that chronic CMP involves not only peripheral nociceptive input but also nociplastic pain mechanisms driven by sustained neuroimmune dysregulation and central sensitization. Pharmacopuncture, combining acupuncture point stimulation with localized injection of therapeutic agents, has evolved with the introduction of regenerative biologics such as platelet-rich plasma (PRP). PRP contains concentrated platelets and bioactive growth factors, including VEGF, PDGF, and TGF-β, which exert anti-inflammatory and tissue-reparative effects. Emerging data indicate that PRP pharmacopuncture may reduce pro-inflammatory cytokines (e.g., IL-1β and TNF-α), modulate regulated cell death pathways (e.g., apoptosis and pyroptosis), and promote the restoration of myofascial tissue homeostasis. These mechanisms may contribute to both peripheral tissue repair and attenuation of nociplastic pain processing. This narrative review synthesizes current clinical and experimental evidence on the biological mechanisms and therapeutic potential of PRP pharmacopuncture in chronic CMP. Available studies report meaningful improvements in pain intensity and functional outcomes compared with conventional acupuncture or pharmacotherapy alone. However, substantial methodological heterogeneity may arise from PRP preparation protocols, acupoint selection, and outcome measures, limiting the ability to draw definitive conclusions. High-quality randomized controlled trials incorporating standardized protocols and mechanistic biomarkers are required to establish PRP pharmacopuncture as an evidence-based integrative treatment for chronic CMP.